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Verburg, Melissa, Ingrid B. Renes, Helen P. Meijer,
Jan A. J. M. Taminiau, Hans A. Bu¨ller, Alexandra W. C.
Einerhand, and Jan Dekker. Selective sparing of goblet
cells and Paneth cells in the intestine of methotrexate-
treated rats. Am J Physiol Gastrointest Liver Physiol 279:
G1037–G1047, 2000.—Proliferation, differentiation, and cell
death were studied in small intestinal and colonic epithelia of
rats after treatment with methotrexate. Days 1–2 after treat-
ment were characterized by decreased proliferation, in-
creased apoptosis, and decreased numbers and depths of
small intestinal crypts in a proximal-to-distal decreasing
gradient along the small intestine. The remaining crypt ep-
ithelium appeared flattened, except for Paneth cells, in which
lysozyme protein and mRNA expression was increased. Re-
generation through increased proliferation during days 3–4
coincided with villus atrophy, showing decreased numbers of
villus enterocytes and decreased expression of the entero-
cyte-specific genes sucrase-isomaltase and carbamoyl phos-
phate synthase I. Remarkably, goblet cells were spared at
villus tips and remained functional, displaying Muc2 and
trefoil factor 3 expression. On days 8–10, all parameters had
returned to normal in the whole small intestine. No metho-
trexate-induced changes were seen in epithelial morphology,
proliferation, apoptosis, Muc2, and TFF3 immunostaining in
the colon. The observed small intestinal sparing of Paneth
cells and goblet cells following exposure to methotrexate is
likely to contribute to epithelial defense during increased
vulnerability of the intestinal epithelium.
villus atrophy; chemotherapy; gene expression; damage and
regeneration
THE INTESTINAL EPITHELIUM forms a dynamic system of
continuous proliferation, differentiation, and cell
death. In the crypt compartment, stem cells and pro-
liferating cells produce new epithelial cells. During
migration from the proliferative compartment toward
the crypt base, villus tips (small intestine), or surface
epithelium (colon), epithelial cells differentiate into
distinct cell types that can be identified using morpho-
logical criteria and through expression of specific
genes. At villus tips and at the surface epithelium, cells
are shed into the lumen or become phagocytosed after
apoptosis (7).
Enterocytes form the largest population of epithelial
cells. They express highly selective enzymes and trans-
porter proteins that regulate nutrient uptake and fluid
housekeeping in a well-orchestrated manner. Specific
differences exist in the functions of enterocytes along
the proximal-to-distal axis of the intestine, which are
reflected in the regulated expression of region-specific
genes (28). The vulnerable epithelium is protected
against mechanical stress, luminal substances, and
pathological microorganisms through the secretion of
mucus. The mucus barrier consists mainly of mucins,
which are large glycoproteins that are secreted by
goblet cells (25, 27). The relative numbers of goblet
cells increase along the proximal-to-distal axis, consti-
tuting only a few percent in the duodenum but up to
;20% of the cells in the colon. Paneth cells, only
present in the small intestine, are localized at the very
base of the crypts and secrete antimicrobial polypep-
tides such as lysozyme and growth factors into the
lumen. In contrast to the enterocytes and goblet cells,
which have a lifespan of only 3 days in the rat, the
Paneth cells have a slower turnover, resulting in a
lifespan of ;3 wk (2). Another small group of slowly
renewing cells is formed by the enteroendocrine cells,
which specialize in the primarily mucosal secretion of
hormonal peptides (3). Collectively, the epithelial cells
maintain a high barrier function, principally through
the presence of a tight junctional network between
their plasma membranes, to separate the luminal con-
tent from the body’s interior (29).
The use of the cytostatic drug methotrexate (MTX) in
anticancer treatments may severely impair intestinal
epithelial function and therefore constitutes a dose-
limiting factor in treatment schedules (20). Like other
chemotherapeutics, it induces diarrhea and anorexia,
accompanied by malabsorption, malnutrition, and de-
hydration. Research has been performed on the effects
of cytostatic drugs, including MTX, on the epithelium
of the small intestine in animals. The use of animal
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experiments allows the analysis of the effects of a
specific drug over time in all regions of the intestine,
which would be impossible to perform in humans. Pre-
viously, it was shown in rats that MTX inhibited intes-
tinal epithelial proliferation, which was followed by
villus atrophy in the rat small intestine (23). Further-
more, during damage the levels of glycohydrolase en-
zyme activities strongly decreased in rat jejunum (23),
suggesting enterocyte malfunction. In other studies
using the cytostatic drug 5-fluorouracil, expression of
the aminopeptidase transporter 1 appeared resistant
to similar mucosal injury in rat ileum (24). In each
study, the epithelium was able to fully regenerate.
During regeneration, the epithelial cells increased in
number and the enterocytes regained their degrada-
tive and absorptive functions. In several studies, the
prophylactic or therapeutic administration of particu-
lar growth factors, vitamins, or inhibitors of apoptosis
could enhance the regenerative capacities of the epi-
thelium in vivo (4, 8, 9, 11, 13, 18).
Despite numerous investigations, very little is
known about the fate of the individual epithelial cell
types after exposure to cytostatic drugs. Also, little
attention was paid to the response of the large intes-
tine to MTX or other cytostatics. Knowledge of cell
type-specific and region-specific variation in MTX sen-
sitivity is still lacking, which is essential for the devel-
opment of oral treatments in humans that could main-
tain or enhance intestinal epithelial cell functions
during and after exposure to cytostatic drugs. In this
study, we investigated in rats the mechanism of intes-
tinal epithelial damage and regeneration in all regions
of the small intestine and in the proximal colon using
specific (immuno-) histochemical stainings for prolifer-
ating cells, enterocytes, goblet cells, Paneth cells, and
apoptotic cells. Furthermore, we quantified the expres-
sion of cell type-specific differentiation markers at the
mRNA level. This will give us insight into the func-
tional capacities of the epithelium during each phase of
MTX-induced damage and subsequent regeneration.
MATERIALS AND METHODS
Unless otherwise indicated, chemicals and enzymes were
obtained from the following manufacturers: Merck (Darm-
stadt, Germany); Sigma (St. Louis, MO); BDH (Poole, Dorset,
UK); Boehringer Mannheim (Mannheim, Germany); Vector
Laboratories (Burlingame, CA); DAKO (Glostrup, Denmark);
Amersham (Little Chalfont, UK); and GIBCO BRL (Gaith-
ersburg, MD).
Animals. Male Wag/Rij rats (Broekman, Utrecht, The
Netherlands), aged 6 wk (120–140 g), were kept in conven-
tional cages (3 rats/cage) in a specific pathogen-free environ-
ment under controlled humidity and a 12:12-h light/dark
cycle (light 7 AM–7 PM) with free access to defined semisyn-
thetic chow (1 mg/kg folic acid; Hope Farms, Woerden, The
Netherlands) and water. The dosage schedule of MTX treat-
ment leading to intestinal damage and regeneration without
causing death was obtained from pilot studies. At 10 AM (day
21), 20 mg/kg body wt MTX (Ledertrexate SP Forte; Cyan-
amid Benelux, Etten-Leur, The Netherlands) was injected
intravenously under light anesthesia. Twenty-four hours
later (day 0), a second injection of 10 mg/kg body wt MTX was
given. Control animals received equivalent volumes of 0.9%
NaCl solution both times. During the experiment, food in-
take, body weight, diarrhea, and malaise were recorded
daily. At days 1, 2, 3, 4, 5, 6, 8, and 10, the MTX-treated rats
were killed by decapitation. Control animals were killed at
day 8. To analyze epithelial proliferation, 50 mg/kg body wt
bromodeoxyuridine (BrdU; Sigma), dissolved in sterile PBS
(pH 7.4) was injected intraperitoneally 24 h before decapita-
tion. Rats that were killed at day 1 were injected with BrdU
17 h before decapitation. Segments of duodenum (proximal 3
cm of the small intestine), jejunum (anatomic middle of the
small intestine), ileum (distal 3 cm of the small intestine),
and proximal colon (proximal 3 cm of the colon) were rinsed
in PBS, fixed in 4% formaldehyde (Merck) dissolved in PBS,
dehydrated, and embedded in Paraplast Plus (Sherwood
Medical, Den Bosch, The Netherlands) according to standard
procedures for (immuno-) histochemistry. In addition, small
segments of the jejunum (0.5 cm) of each animal were frozen
in liquid nitrogen and further stored at 280°C for RNA
isolation.
Morphology. Epithelial morphology and apoptosis were
analyzed on 6-mm-thick tissue sections after standard histo-
chemical staining methods using either alcian blue (BDH)
and nuclear fast red (Merck) or hematoxylin (Vector Labora-
tories) and eosin (Merck) (HE). Crypt depth and villus height
were measured manually in well-orientated sections (5
measurements zregion21 zrat21) using a micrometer (Nikon,
Bunnik, The Netherlands) mounted in an Eclipse E800 Mi-
croscope (Nikon, Japan).
Immunohistochemistry. Proliferation and antigen expres-
sion were detected by immunohistochemistry. Tissue sec-
tions were deparaffinized with xylene (Merck), rehydrated in
graded ethanol solutions, and treated with 1.5% (vol/vol)
H2O2 (Merck) in PBS for 30 min at room temperature to
remove endogenous peroxidase activity. Antigen unmasking
was carried out by heating the sections for 10 min in 0.01 M
sodium citrate (pH 6.0; Merck) at 100°C. For the anti-BrdU
antibodies, all sections were incubated using 20 mg/ml pro-
teinase K (Boehringer) in PBS for 7.5 min and colonic sec-
tions were additionally treated with 2 N HCl (Merck) for 90
min before incubation with the protease. Nonspecific protein
binding was blocked using a buffer containing 10 mM Tris
(Merck), 5 mM EDTA (Merck), 0.15 M NaCl (Merck), 0.25%
gelatin (Sigma), and 0.05% Tween 20 (Merck), pH 8.0. All
sections were incubated overnight (4°C) using the primary
mouse monoclonal antibodies anti-BrdU (1:100–400; Boehr-
inger), anti-human proliferating cell nuclear antigen (PCNA,
1:2,500; Boehringer), anti-human Muc2 (1:100; see Ref. 26) or
the rabbit polyclonal antibodies anti-human lysozyme (1:50;
DAKO), anti-calf alkaline phosphatase (AP, 1:1,500; DAKO),
anti-rat carbamoylphosphate synthase I (CPSI, 1:5,000; see
Ref. 5), anti-rat sucrase-isomaltase (SI, 1:6,000; see Ref. 32),
anti-rat trefoil factor 3 (TFF3, 1:6,000) or anti-rat carbonic
anhydrase I (CAI, 1:6,000). Immunodetection was performed
using a Vectastain elite ABC kit, peroxidase-conjugated (Vec-
tor Laboratories) and 0.5 mg/ml 3,39-diaminobenzidine
(Sigma) in imidazole buffer containing 30 mM imidazole
(Merck) and 1 mM EDTA (Merck), pH 7.0. Sections were
counterstained using ready-to-use hematoxylin mounted in
Entellan (Merck) and analyzed under an Eclipse E800 Mi-
croscope. To investigate whether the observed sparing of
goblet cells during villus atrophy was statistically significant,
Muc2-positive cells were counted in villi of the jejunum until
day 4 after MTX. Ten crypt-villus axes were chosen per
animal in well-orientated sections. The number and ratio of
Muc2-positive cells in the lower and upper halves of the villi
of control and MTX-treated rats were compared using the
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Mann-Whitney U-test. Similarly, the number of lysozyme-
positive cells were counted in 10 jejunal crypts/animal until
day 4 to investigate the MTX resistance of Paneth cells.
Histochemistry. Differentiated enterocytes expressing AP
activity were localized on deparaffinized, rehydrated tissue
sections in an one-step assay using 50 ml nitroblue tetrazo-
lium solution (Vector Laboratories) and 37.5 ml bromo-
chloroindolyl phosphate solution (Vector Laboratories) in 10
ml Tris (pH 9.5) as described by the manufacturer. After a
12-min incubation at room temperature, the reaction was
stopped in distilled water. After mounting in Entellan, brush
border staining was analyzed under an Eclipse E800 micro-
scope.
Terminal transferase deoxyuridine nick-end labeling. For
the detection of apoptotic cells, the terminal transferase
deoxyuridine nick-end labeling (TUNEL) method was used
as described previously, with slight modifications (17).
Briefly, following deparaffinization and rehydration, sections
were incubated for 7.5 min with 20 mg/ml proteinase K at
room temperature. After rinsing in PBS and removal of
endogenous peroxidase activity for 20 min using 1.5% (vol/
vol) H2O2 in PBS, sections were preincubated in 25 mM Tris,
pH 6.6, 200 mM potassium cacodylate, 0.2 mM EDTA, and
0.25 mg/ml BSA for 10 min. Subsequently, new buffer was
added, including 1 mM cobalt chloride, 0.4 pM digoxigenin-
11-deoxyuridine triphosphate (Boehringer), and 25 U/ml ter-
minal transferase (Boehringer) for a 90-min incubation at
37°C. Negative controls were included by omitting terminal
transferase. Positive controls were incubated in 0.5 U/ml
DNAse (Boehringer)-containing buffer, including 50 mM Tris
(pH 9.2), 14 mM ammonium sulfate (Merck), 20% (vol/vol)
dimethyl sulfoxide (Merck), 0.3% (vol/vol) Tween 20, 50 mM
MgCl2 (Boehringer), and 100 mM CaCl2 (Boehringer), before
incubation with the terminal transferase. The reaction was
stopped for 15 min by using 300 mM NaCl and 30 mM sodium
citrate and was subsequently blocked for 10 min with 2%
BSA in PBS. After rinsing in PBS, the sections were incu-
bated overnight at 4°C using peroxidase-conjugated Fab
fragments (1:2,000; Boehringer) in PBS. Binding of Fab frag-
ments was visualized using 0.5 mg/ml ml 3,39-diaminobenzi-
dine dissolved in imidazole buffer. Serial sections were
stained using HE for comparison of TUNEL reaction with the
known morphological criteria (nuclear shrinkage, apoptotic
bodies) (7).
Northern blots. Total RNA was isolated from frozen jejunal
segments (0.5 cm) using TRIzol reagent (GIBCO). Cell type-
specific mRNA expression was quantified on both Northern
and Northern spot blots. For the detection of Muc2 and CPSI
mRNA, 2 mg total RNA was spotted directly onto nylon
membranes (Hybond-N1, Amersham) using a Bio-Rad spot
blot device (Bio-Rad, Hercules, CA). To detect SI, TFF3, and
lysozyme mRNA, 10 mg of total RNA was separated on
1–1.2% agarose gels (Boehringer) containing 3.5% glyoxal
(Merck) before blotting. All blots were hybridized using spe-
cific 32P-labeled cDNA probes. Hybridization signals were
quantified using a PhosphorImager (Molecular Dynamics)
after 1–3 days exposure time. The following probes were
used: A 827-bp EcoR I fragment of rat SI mRNA (12), a 1.9-kb
EcoR I fragment of rat CPSI mRNA (19), 1 kb of rat lysozyme
mRNA (33), and 438 bp of rat TFF3 mRNA (22). For the
construction of a rat Muc2 probe, RT-PCR was performed on
colonic RNA using the primers ACCTGTCGACTGGTAGAG-
GAGATTACCCCC and GCTCTAGATCACATGTGGTCAG-
GTTGC, based on the rat Muc2 coding sequence (31). Rat
Muc2 (bp 506–1560, 1.1 kb) was amplified and cloned in the
Sal I-Xba I sites of pBluescript SK1 (Promega, Madison,
WI). Hybridized signals were corrected for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA expression to
correct for the amount of loading by using 1.4 kb GAPDH
mRNA as a probe.
Statistical analysis. Statistical analysis was performed on
crypt depth, villus height, goblet cell and Paneth cell num-
bers, and mRNA expression using the Mann-Whitney U-test.
Due to time-dependent intraanimal variations, data from two
consecutive time points were pooled. A P value of ,0.05 was
considered statistically significant.
RESULTS
Clinical symptoms. The intake of food and the gain in
body weight decreased immediately after the first in-
jection of MTX and lasted until day 4. In Fig. 1, average
changes in the body weight of control and MTX-treated
rats are shown in time, relative to their individual
weight at the onset of treatment at day 21. Food
consumption in the MTX-treated group was minimal at
days 2 and 3, when only 25% (i.e., 4 g/rat) of the intake
of control rats was observed (not shown). By then, the
MTX-treated rats had lost 2–10% of their initial body
weight. This weight loss was in part the result of
dehydration because all MTX-treated rats developed
diarrhea from day 2 until day 6. Recovery was seen
from day 3 onward, accompanied by regain of appetite
and increased gain in body weight compared with con-
trols. During the experiment, no effect of MTX treat-
ment on water intake was observed (not shown).
Proliferation. The effects of MTX on intestinal epi-
thelial proliferation were analyzed through detection
of incorporated BrdU, injected the day before the rats
were killed. Because of the 24-h interval between in-
jection and killing, BrdU-positive cells were not re-
stricted to the crypts but were also found up to one-
third of the length of the villi in all small intestinal
regions of control rats due to migration of the cells (Fig.
2, A–C). In each small intestinal region, MTX com-
pletely inhibited epithelial proliferation, since BrdU
injected 5 h after the final dose of MTX could not be
detected in epithelial cells in any of the small intestinal
Fig. 1. Methotrexate (MTX)-induced effects on body weight. For each
rat, body weight at the onset of treatment (day 21) was set arbi-
trarily at 100%. Rats of the control group ( n ) and the MTX-treated
group (E) were injected intravenously using NaCl or MTX, respec-
tively, at day 21 and day 0 (arrows). Individual changes in body
weight relative to day 21 were recorded daily and averaged per
group. Standard deviations are given in percentages of absolute
weights. Rats of the MTX-treated group were killed sequentially
until day 10. Control rats were killed at day 8.
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regions (Fig. 2, D–F). An induction of epithelial prolif-
eration in the small intestine occurred between 24 and
48 h after the final dose of MTX in a region-dependent
manner. A minor increase in the amount of BrdU
staining was seen in duodenal crypts at day 2 (Fig. 2G).
Slightly more BrdU-labeled cells were seen in the je-
junum at day 2 (Fig. 2H), whereas the highest induc-
tion of proliferation was seen in the ileum (Fig. 2I). At
day 3, BrdU-positive cells were abundantly covering
the crypt epithelium and reached up to one-third of the
length of the villi in all small intestinal regions (not
shown). The numbers of BrdU-positive cells were fur-
ther increased at day 4 in each region of the small
intestine such that labeling was seen along the entire
crypt-villus axes (Fig. 2, J–L). Between days 5 and 8,
the numbers of BrdU-positive cells decreased toward
control patterns in each of the small intestinal regions
(Fig. 2, M–R).
Inhibition of proliferation was not seen in the colon
in the days following MTX treatment because the
Fig. 2. Effects of MTX treatment on epithelial proliferation. Bromodeoxyuridine (BrdU) incorporation was detected
immunohistochemically in the duodenum (A, D, G, J, M, P), jejunum (B, E, H, K, N, Q), ileum (C, F, I, L, O, R) and
colon (S, T, U) of control and MTX-treated rats. In control rats, proliferation and migration resulted in BrdU-
positive cells up to one-third of the villi in the small intestine (A–C) and in the midcrypts of the colon (S). After MTX
treatment, proliferation was absent at day 1 along the entire small intestine (D–F) and proliferation returned at
first in the distal small intestine at day 2 (G–I). Maximal proliferation was seen at day 4 along the entire small
intestine (J–L). Proliferation decreased gradually toward control patterns at day 6 (M–O) and day 8 (P–R). No
decrease in BrdU staining was seen at day 1 in the colon (T). Hyperproliferation was seen in the colon of some rats
at day 6 (U). Bars, 100 mm.
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BrdU-positive cells detected at days 1–3 in the mid-
crypt area remained very similar to controls (Fig. 2, S
and T). A remarkable induction of proliferation was
observed in the colon between days 4 and 6, when
BrdU labeling occurred along the entire colonic crypt
epithelium (Fig. 2U). However, this colonic hyperpro-
liferation was not seen in each animal. After day 6, the
detection of BrdU in the colon of MTX-treated rats was
comparable to the controls (not shown).
Morphology. Morphological damage and regenera-
tion was analyzed on tissue sections through measure-
ment of the length of the crypts and the villi in the
small intestine and the colon. Due to time-dependent
interanimal variations in the response to MTX admin-
istration, measurements from two consecutive days
were pooled in the quantitative analysis of crypt depth
and villus height (Fig. 3). Following the second MTX
injection, the crypt depths were decreased in all small
intestinal regions at days 1 and 2 compared with con-
trols. This decrease was only significant in duodenum
and jejunum, where crypt depths were 80% and 60% of
controls, respectively. In all small intestinal regions,
the crypts were significantly elongated on days 3 and 4
compared with days 1 and 2. The small intestinal
crypts were further elongated on days 5 and 6 com-
pared with controls or with days 3 and 4. Between days
8 and 10, the crypt depth was comparable to controls in
all small intestinal regions. In the colon, no significant
changes occurred in the average crypt depth following
MTX administration (data not shown). Nevertheless, it
is worth mentioning that in some animals the colonic
crypts were enlarged to 150% of control length between
days 4 and 6, coinciding with increased BrdU incorpo-
ration in these animals, as shown in Fig. 2U.
The small intestinal villi progressively shortened
between days 1 and 4 following MTX treatment com-
pared with the length of the villi in controls. This villus
atrophy was only significant in the jejunum (75% of
control values) and less pronounced in duodenum (80%
of control values) and ileum (85% of control values).
Between days 5 and 10, the villi regenerated to normal
lengths in all small intestinal regions. However, during
the regeneration phase at days 5 and 6, the ileal villi
temporarily exceeded the lengths of normal ileal villi
(140% of controls).
Next to MTX-induced changes in small intestinal
crypt and villus sizes, a morphological characteristic of
epithelial damage became apparent when judged on
HE-stained sections. At days 1 and 2, epithelial dam-
age in the small intestine was characterized by a re-
duction in the number of crypts. In the remaining
crypts, the epithelial cells appeared flattened. This
damage was most severe in the duodenum (Fig. 4A).
Toward the ileum, epithelial damage in the crypts was
less pronounced (Fig. 4, B and C), whereas in the colon
morphological changes were absent (Fig. 4D). Epithe-
lial cell damage was also observed on the villi at later
stages in all small intestinal regions. At days 3 and 4,
the villi showed reduced numbers of epithelial cells and
the remaining cells were flattened, e.g., day 4 of the
jejunum (Fig. 4, E and F). Similar to the observed crypt
damage, villus damage was also less severe toward the
ileum (not shown). By days 5 and 6, the villus epithelial
cells appeared normal in number and in morphology in
each small intestinal region (not shown).
MTX-induced apoptosis. In each of the small intes-
tinal regions of controls, only an occasional crypt cell
was TUNEL positive and most crypts were TUNEL
negative (Fig. 5A). In MTX-treated rats, the number of
TUNEL-positive cells was markedly increased at days
1 and 2 in the small intestinal crypts, but not on the
villi (Fig. 5B). MTX-induced TUNEL-positive cells oc-
curred in the crypts in all small intestinal regions,
suggesting enhanced apoptosis at days 1 and 2 along
the entire small intestine. The induction of apoptosis in
small intestinal crypts at days 1 and 2 was further
supported by the increased appearance of nuclear
shrinkage and apoptotic bodies in serial HE-stained
sections (not shown). In the colon, the number of
TUNEL-positive cells was not altered in the crypts
after MTX treatment compared with controls (not
shown). Also, on serial sections stained with HE, no
signs of altered apoptosis were observed in the colon
(not shown).
Epithelial gene expression during MTX-induced
damage and regeneration. To localize differentiated
enterocytes in the small intestine during epithelial
damage, expression of AP and SI was detected immu-
nohistochemically along the small intestine. In the
jejunum of control small intestine, the brush borders of
villus enterocytes were AP and SI positive (not shown).
During maximal villus atrophy and epithelial restitu-
Fig. 3. Effects of MTX treatment on crypt depth and villus height in
duodenum (filled bars), jejunum (open bars), and ileum (hatched
bars). Mean crypt depth (downward) and mean villus height (up-
ward) is shown per group per region. Crypt depth decreased in the
small intestine until day 2. In the proximal regions, this decrease
was significant compared with controls (P , 0.05). During crypt
regeneration on days 3 and 4, they were enlarged compared with
days 1 and 2 in all small intestinal regions (P , 0.05). Crypt
elongation continued on days 5 and 6, during which they even
exceeded control values in duodenum and ileum. The length of the
small intestinal villi decreased until day 4 after MTX treatment.
Only in the jejunum was this decrease significant (P , 0.05). Small
intestinal villi regenerated on days 5 and 6, during which they were
elongated in the ileum compared with controls. At days 8 and 10, the
length of small intestinal crypts and villi returned within the range
of controls. Values are means 6 SE. *P , 0.05 vs. the previous group
of the time course and **P , 0.05 vs. controls as analyzed using the
Mann-Whitney U-test.
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tion (days 3–4), villus enterocytes were reduced in
number but were still AP and SI positive (e.g., Fig. 6G).
To verify the functionality of AP during damage, its
activity was localized on serial sections. The localiza-
tion of AP activity in control jejunum was comparable
to the immunohistochemical localization of the protein
(Fig. 6A) and did not change during villus atrophy, as
shown on day 4 (Fig. 6B). Similar results for AP and SI
were also obtained for the duodenum and the ileum
(not shown). Interestingly, in control jejunum, intra-
cellular staining of the SI precursor is restricted to
villus enterocytes localized close to the crypt-villus
junction (not shown). The late onset of enterocyte dif-
ferentiation during villus regeneration is reflected by
the detection of SI in the Golgi region of enterocytes on
villus tips on day 4 (Fig. 6H).
The presence and the functionality of goblet cells
during MTX-induced damage and regeneration was
analyzed in each small intestinal region using alcian
blue staining of mucins in combination with the immu-
nodetection of Muc2 and TFF3. In control small intes-
tine, goblet cells increased in number toward the distal
small intestine and were evenly distributed along the
crypt-villus axis (Fig. 6A). At days 1 and 2, the number
of goblet cells was decreased in the small intestinal
crypts but not on the villi, as could be demonstrated
using alcian blue staining and Muc2 or TFF3 immuno-
staining. This goblet cell depletion was most pro-
nounced in the duodenum and was less pronounced
toward the ileum (not shown). At days 3 and 4, goblet
cells had returned in the crypts and became increas-
ingly abundant on the tops of the villi in each region of
the small intestine (e.g., Fig. 6B). These villus goblet
cells, identified by alcian blue staining, were never
positive for BrdU in double stainings (Fig. 6C). Appar-
ently, the goblet cells but not the enterocytes were
Fig. 4. Hematoxylin and eosin-stained sections
showing MTX-induced changes in epithelial mor-
phology along the small intestine and colon.
Crypt damage was seen in the small intestine
and was characterized by loss of crypt cells and
flattening of remaining epithelium (arrows).
Crypt damage was most severe on day 2 in the
duodenum (A). Less severe damage was seen in
the jejunum (B) and the ileum (C). No epithelial
abnormalities were seen in the colon on day 2
(D). During villus atrophy on days 2–4 in all
small intestinal regions, high numbers of epithe-
lial cells were lost and the remaining cells ap-
peared flattened, as shown in the jejunum on day
4 (F) compared with controls (E). v, Villus; s,
serosal side. Bars, 50 mm (A–D) and 10 mm
(E–F).
Fig. 5. MTX-induced apoptosis in the
small intestine of MTX-treated rats. In-
creased numbers of terminal trans-
ferase deoxyuridine nick-end labeling-
positive cells (arrows) were seen in the
crypts of the jejunum at days 1 (B) and
2 (C) compared with controls (A). v, Vil-
lus; s, serosal side; *, crypts. Sections
were counterstained with hematoxylin.
Bars, 50 mm.
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spared from extrusion, at least in the 24-h period
following BrdU injection. This notion was confirmed
using PCNA immunostaining as proliferation marker
(Fig. 6D). The accumulating villus tip goblet cells were
expressing both Muc2 (Fig. 6E) and TFF3 (Fig. 6F). To
verify whether the increase in upper-villus goblet cells
was statistically significant during villus atrophy,
Muc2-positive cells were counted in three zones along
the crypt-villus axis of control and MTX-treated jeju-
num as a representative of the entire small intestine.
In the jejunum of control animals, the goblet cells were
almost evenly distributed along the crypt-villus axis
(Table 1). From day 5 onward, the distribution pattern
of goblet cells was normal in the small intestine (not
shown).
Differentiated Paneth cells were identified in the
base of the small intestinal crypts by their expression
of lysozyme. Both in controls and in MTX-treated rats,
Fig. 6. Effects of MTX treatment on the (immuno-) histochemical detection of intestinal epithelial differentiation
markers in rat jejunum and colon. A and B: alkaline phosphatase (AP) activity (dark blue) and alcian blue double
staining in the jejunum of control (A) and MTX-treated (B) rats. AP activity remained detectable in the brush
border of jejunal enterocytes during villus atrophy on day 4 after MTX treatment as in controls, despite severe cell
loss. C and D: alcian blue and BrdU double staining of a jejunal section on day 4 after MTX treatment (C) and a
serial section stained for proliferating cell nuclear antigen (PCNA; D). During MTX-induced villus atrophy, goblet
cells (in blue) accumulated at villus tips along the small intestine surrounded by BrdU- or PCNA-positive cells (in
brown). E and F: goblet cell-specific expression of Muc2 (E) and trefoil factor 3 (TFF3; F) at villus tips during
MTX-induced villus atrophy on day 4 after MTX. G and H: sucrase-isomaltase (SI) expression in rat jejunum on day
4 after MTX treatment. During MTX-induced villus atrophy, SI was decreased (G) compared with controls (not
shown). The intracellular staining of SI precursor detected high up the villus (arrows) indicates the late moment
of enterocyte differentiation (H). I and J: lysozyme immunostaining in Paneth cells of control jejunum (I) and at
day 2 after MTX (J). Lysozyme expression was increased during crypt damage on days 1 and 2 after MTX
treatment compared with controls. Bars, 50 mm (C, D, H–J) and 100 mm (A, B, E–G).
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a gradual increase in the number of Paneth cells per
crypt was seen from the duodenum toward the ileum
(not shown). At days 1 and 2 after MTX treatment, the
amount of lysozyme immunostaining was strongly in-
creased in each of the small intestinal regions com-
pared with controls, with a maximum at day 2 (Fig. 6,
I and J). During regeneration of the small intestinal
crypts, from days 3 to 4, lysozyme immunostaining
returned to control levels (not shown).
In the colon, no changes were observed in the
amount and distribution of either alcian blue-, Muc2-,
or TFF3-positive goblet cells following MTX treatment
(not shown). Differentiated colonic enterocytes were
stained by their expression of CAI, a bicarbonate-pro-
ducing enzyme present in the cytosol of colonic surface
enterocytes. MTX treatment did not affect colonic CAI
expression, except for some animals in which, during
the late regeneration phase on days 6 and 8, fewer
CAI-positive cells were found in the colonic surface
epithelium. This decrease may have been related to
colonic hyperproliferation mentioned in Proliferation
(not shown).
Sparing of goblet cells and Paneth cells. To investi-
gate whether the observed accumulation of goblet cells
at villus tips was statistically significant, Muc2-posi-
tive cells were counted along the crypt-villus axis, as
described in MATERIALS AND METHODS. The numbers and
distribution of Muc2-positive cells along the crypt-vil-
lus axis in the jejunum of controls and at days 1 and 2
and days 3 and 4 after MTX treatment are summarized
in Table 1. In the two days following MTX treatment,
the number of Muc2-positive cells was ;50% reduced
in both the upper half and the lower half of the villus
(Table 1). In the lower half of the villi, the number of
Muc2-positive cells was still decreased on days 3 and 4,
although in contrast they had increased in villus tips to
numbers that did not differ statistically from controls.
This increase in Muc2-positive cells on villus tips on
days 3 and 4 was statistically significant compared
with days 1 and 2 and supported the observation of
goblet cell sparing at villus tips during MTX-induced
villus atrophy (Fig. 6).
The number of lysozyme-positive cells in the deeper
crypts were counted on days 1–4 after MTX treatment
and compared with controls to verify whether the num-
ber of Paneth cells was affected by MTX (Table 1).
However, the number of lysozyme-positive Paneth cells
on days 1 and 2 and on days 3 and 4 were not statis-
tically different from control values.
Quantitation of epithelial mRNA expression. Mor-
phological damage was compared with alterations in
levels of mRNA expression in the jejunum of MTX-
treated rats using quantitative Northern blots. mRNA
expression of CPSI and SI, markers for crypt and villus
enterocytes, respectively, both decreased after MTX
treatment (Fig. 7). CPSI decreased to 15% of control
levels in 2 days and SI to 45% of control levels in 4
days. The mRNA expression of both enterocyte mark-
ers increased thereafter and reached control levels on
days 5 and 6. On days 8 and 10, the expression of CPSI
and SI mRNA had further increased to 150% of control
levels.
Goblet cell-specific mRNA expression was quantified
using TFF3 and Muc2 as markers. In contrast to the
enterocyte markers, TFF3 and Muc2 mRNA levels
were maintained during damage on days 1 and 2 (Fig.
7). Lowest levels of TFF3 mRNA were seen during a
period of extensive cell loss on days 3 and 4 (50% of
control), and lowest levels of Muc2 mRNA were seen
during regeneration on days 5 and 6 (55% of control).
Both TFF3 and Muc2 mRNA levels gradually in-
creased to control levels on days 8–10.
Lysozyme mRNA expression was quantified to inves-
tigate Paneth cell function. In agreement with the
observed increase in lysozyme immunostaining, ly-
sozyme mRNA was increased to 165% of control levels
during damage on days 1 and 2 (Fig. 7). In the days
thereafter, lysozyme mRNA expression was not statis-
tically different from controls, except for a second
phase of induction occurring on days 8–10.
Table 1. Numbers of goblet cells and Paneth cells in
the jejunum of MTX-treated rats
Control Days 1 and 2 Days 3 and 4
Goblet cells
Villus tip 11.0061.70 5.6061.80* 9.5062.50†
Villus base 14.3060.70 7.7061.98* 6.0062.80†
Ratio, base:tip 1.3660.14 1.6460.43* 0.6860.29*†
Paneth cells 3.0760.23 3.5260.38 2.7760.20
Average numbers of goblet cells and Paneth cells (mean6SD)
were determined in well-orientated tissue sections by counting
Muc2-positive and lysozyme-positive cells, respectively. For goblet
cells, 2 zones along the villus axis were defined (see MATERIALS AND
METHODS). Statistical analysis was performed using the Mann-Whit-
ney U-test. *P , 0.05 vs. control; †P , 0.05 vs. days 1 and 2.
Fig. 7. Intestinal epithelial mRNA expression in normal and MTX-
treated rats. mRNA expression was quantified on Northern blots and
corrected for the amount of glyceraldehyde-3-phosphate dehydroge-
nase mRNA. Expression of carbamoyl phosphate synthase I (cross-
hatched bars) and SI (hatched bars) mRNA through enterocytes
decreased during damage and gradually increased during and after
regeneration to levels higher than control on days 8 and 10. Expres-
sion of goblet cell-specific Muc2 (gray bars) and TFF3 (open bars)
mRNA remained stable during crypt damage (days 1 and 2) but were
temporarily decreased during extensive cell loss on the villi (days 3
and 4). Expression of both markers returned to normal over the next
few days. Lysozyme mRNA expression (filled bars) as marker for
Paneth cell differentiation was increased during crypt damage and
during late regeneration. *P , 0.05 vs. control by Mann-Whitney
U-test.
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DISCUSSION
The use of rats in this study allowed us to identify
regional variation in intestinal epithelial sensitivity
toward MTX and to gain insight into mechanisms of
intestinal epithelial damage and regeneration after
exposure to cytotoxic concentrations of MTX. These
regional differences were reflected by a decrease in the
degree of MTX-induced crypt damage along the proxi-
mal-to-distal axis of the intestine.
Analysis of epithelial proliferation after two consec-
utive days of MTX administration, using BrdU incor-
poration as a marker, demonstrated an inhibition of
DNA synthesis in the epithelium of the entire small
intestine until at least 5 h after the final dose. Prolif-
eration of the colonic epithelium, on the other hand,
was not inhibited compared with controls. In the small
intestine, proliferation recurred ;24 h after the final
dose of MTX. This induction of proliferation was stron-
gest in the ileum and decreased toward the duodenum.
In vivo and in vitro proliferation studies in both human
and rat have demonstrated a gradient of crypt cell
production rates along the duodenal-colonic axis. In
rat small intestine, the crypt cell production rate
(cells zcrypt21 zh21) decreased from 28 in the duodenum
to 12 in the ileum, whereas in the colon a decrease from
7.7 to 3 has been reported from proximal to distal (1, 6).
The gradual decrease in crypt cell production rates
from the duodenum toward the colon could explain the
different sensitivity toward MTX.
Together with an inhibition of cell proliferation,
MTX also induced apoptosis on days 1 and 2 in the
proliferative region of small intestinal crypts, as
judged by morphological criteria and TUNEL staining.
In contrast, MTX-induced cell death was not observed
in the colon. It is possible that the difference in apo-
ptosis between small and large intestine is the result of
regional differences in cell cycle control mechanisms
following cellular damage, for instance, through the
lower expression of p53 and the higher expression of
bcl-2 in the colon compared with the small intestine
(16). On the other hand, the colonic resistance to MTX-
induced cell death could be directly related to the
relative slow cell turnover in the colon, leading to only
minor damage and less induction of cell death.
Morphological damage in the crypts of the small
intestine paralleled increased apoptosis on days 1 and
2. The observed flattening of the remaining crypt cells
most likely represents epithelial restitution, which
prevents breaches in the epithelial barrier. During
crypt damage, CPSI mRNA expression was sixfold de-
creased in the jejunum, indicating the loss of crypt
enterocyte function. Regeneration of the atrophic
crypts started on day 3 in the small intestine via
hyperproliferation and hyperplasia.
During MTX-induced villus atrophy (days 3 and 4),
epithelial restitution was observed on the villi. Fur-
thermore, SI mRNA expression was threefold de-
creased in the jejunum and paralleled the loss of villus
enterocytes. It was previously shown that during MTX-
induced villus atrophy, activities of the brush border
glycohydrolytic enzymes SI and lactase are strongly
downregulated in the small intestine (23). The absence
of glycohydrolases indicates enterocyte malfunctioning
with regard to the degradation and absorption of nu-
trients during villus atrophy. In contrast to the glyco-
hydrolases, no decrease in the enterocytic expression of
AP protein and enzyme activity was found during vil-
lus atrophy. Poelstra et al. (21) have indicated a role for
AP in host defense against endotoxins. It is possible
that expression of this protein is selectively main-
tained after MTX treatment to assist in the mainte-
nance of the epithelial integrity. Especially during ep-
ithelial damage, as induced by MTX, epithelial defense
is of vital importance for survival of the animal.
During regeneration, the lengths of the villi returned
to normal in duodenum and jejunum. However, villus
elongation continued in the ileum, and on days 5 and 6
abnormally long villi (370 mm) were seen compared
with controls (260 mm). It is not clear why hyperplasia
in the distal small intestine is more extensive than in
the proximal small intestine. Also, in other studies
describing the regeneration of intestinal villi following
small bowel resection, increased villus lengths have
been reported (15). It is possible that the feedback
mechanisms involved in balanced cell proliferation are
less controlled in the ileum compared with the proxi-
mal regions of the small intestine, because during
regeneration not only the villi but also the crypts were
.40% longer compared with controls.
As in other studies (30), MTX induced a mild goblet
cell depletion in the small intestine during a 4-day
period of epithelial damage. Immunohistochemistry
demonstrated that the MTX-induced goblet cell deple-
tion mainly affected the villus base, whereas a remark-
able sparing of goblet cells was observed at villus tips
during the days of maximal villus atrophy (days 3 and
4). Furthermore, these accumulating cells were not
labeled with BrdU and were PCNA negative. Appar-
ently, these cells were spared from extrusion via an
adaptive mechanism. Selective sparing of goblet cells
could very well serve a protective function in epithelial
defense via their secretion of mucins and trefoil factors
(14, 25, 27). Indeed, during early damage (days 1 and
2), small intestinal mRNA levels of Muc2 and TFF3
remained unchanged, although the number of goblet
cells was 50% reduced along the villi. Only during
severe villus atrophy, when the amount of epithelial
cells was minimal, was the expression of Muc2 and
TFF3 mRNA decreased. Apparently, goblet cell func-
tion is very important during MTX-induced damage
and therefore maintained. Another cell type with a
pertinent role in epithelial defense is the Paneth cell.
During crypt damage, it expresses 160% of normal
lysozyme mRNA levels and shows increased intensity
of lysozyme immunostaining. The phenomenon of
Paneth cell hyperplasia through MTX treatment was
described morphologically in electron microscopy stud-
ies (10). It is most likely that the slowly renewing
Paneth cells not only have an advantage over the
shorter-lived cell types in survival but that, impor-
tantly, the increased amounts of lysozyme expression
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indicate an increase in secretory capacity that very
likely contributes to protection of the damaged mucosa.
In the colon, no significant changes could be observed
in epithelial morphology and differentiation during the
time course studied. The hyperproliferation and crypt
elongation observed in some animals between days 4
and 6 may have been secondary effects in the response
to MTX. For example, enhanced small intestinal repair
mechanisms could lead to an increase in the amount of
inductive signals, such as carbohydrates, fatty acids,
bile salts, growth factors, and trefoil factors, in the
intestinal lumen that could potentially stimulate pro-
liferation in the downstream compartments.
In summary, MTX was shown to inhibit intestinal
epithelial proliferation in the small intestine but not in
the colon. Subsequent crypt damage was most severe
in the duodenum, but regeneration through hyper-
proliferation was strongest in the distal small intes-
tine. Interestingly, although severe damage could be
induced in the small intestine by using MTX, Paneth
cells, goblet cells, and enterocytes were all able to
contribute to epithelial defense mechanisms. First, a
direct increase of antimicrobial lysozyme expression
was seen in Paneth cells, which remained high until
crypt integrity was fully restored. Second, the goblet
cells remained functional during early damage, were
selectively spared from undergoing cell death, and ac-
cumulated at villus tips during villus atrophy, allowing
secretion of the protective mucin and trefoil factor
molecules. Third, despite the MTX-induced reduction
in enterocyte numbers and SI and CPSI gene expres-
sion during villus atrophy, the putative detoxifier of
endotoxins AP remained actively expressed in the
small intestinal brush border. To gain further insight
into regulatory mechanisms of epithelial defense and
enterocyte function during MTX-induced damage and
regeneration, additional studies are needed that will
allow a quantitative analysis of cell type-specific gene
expression. This insight is necessary to develop further
clinically relevant strategies to protect cancer patients
from intestinal damage during chemotherapy.
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